US healthcare group Carbon Health has made a move into digital care for patients with chronic conditions, buying diabetes-focused startup Steady Health.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh